|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||5.50 - 6.78|
|52 Week Range||5.23 - 39.86|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.60|
NEW YORK, Dec. 11, 2018 -- Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning.
The trial successfully met the secondary endpoint of WI-NRS responder rate at week 4. At week 4, 21% of patients treated with serlopitant achieved a 4-point or greater improvement on the WI-NRS vs. 11% of patients treated with placebo (p=0.039). Assessment of the secondary endpoints of the absolute change in WI-NRS from baseline to day 7 and day 3 for serlopitant compared to placebo showed a greater numerical, but not statistically significant, improvement for the serlopitant group. At every assessed time point in the trial (daily in week 1 and average weekly scores through week 8), the serlopitant treated group demonstrated greater numerical improvement than the placebo group in both the WI-NRS 4-point responder analysis and in the mean change in WI-NRS from baseline. Serlopitant was well-tolerated in this clinical trial. No serious adverse events were reported for serlopitant treated patients. Treatment-emergent adverse events assessed as likely related to treatment were observed with similar frequency in both groups (4.0% for placebo and 4.9% for serlopitant). The consolidated safety summary for serlopitant now includes more than 1,600 evaluable patients, including patients who have received treatment for up to one year.
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
The fireside chat will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.
RADNOR, PA / ACCESSWIRE / November 14, 2018 / Kaskela Law LLC is investigating Menlo Therapeutics Inc. (NASDAQ: MNLO) ("Menlo" or the "Company") on behalf of investors. Menlo is a late-stage ...
NEW YORK, Nov. 14, 2018 -- Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning.
~ Phase 2 Data in Psoriasis Expected December 2018 ~~ New Phase 2 Clinical Trial in Chronic Pruritus of Unknown Origin Expected to Start in Q4 2018 ~~ Prurigo Nodularis Phase 3.
NEW YORK, Nov. 05, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Seaboard Corporation, Menlo.
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. (''Menlo'' or the ''Company'') (NASDAQ: ...
NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics ...
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.
NEW YORK, NY / ACCESSWIRE / October 9, 2018 / No news from Auris Medical Holding yet shares were skyrocketing on Monday. The company has been on a rocket since announcing in late August feedback from a ...
The company raised $137 million in a January IPO, but its stock now is 64 percent lower than the IPO.
Inc. shares fell more than 35% Monday morning as the company said it is ending development of serlopitant for refractory chronic cough after the investigational drug failed to meet primary and key secondary endpoints in a phase 2 trial. Menlo said it is continuing the development of serlopitant for pruritus, or itch, associated with various conditions given two successful phase 2 trials in which the drug showed a reduction in itch in the skin disease prurigo nodularis. Menlo is currently enrolling patients in a pair of phase 3 trials of serlopitant in prurigo nodularis, with data expected in the first half of 2020.
Menlo Therapeutics Inc. (MNLO) a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced top-line results from MTI-110 (TUSSIX), its Phase 2 clinical trial of serlopitant for the treatment of refractory chronic cough. In the primary endpoint analysis of change from baseline in 24-hour cough frequency after 12 weeks of treatment, the serlopitant group had 31% less reduction than the placebo group. In a key secondary analysis of response rates, 54% of placebo treated patients and 44% of serlopitant treated patients experienced a 30% or greater reduction in 24-hour cough frequency at week 12 compared to baseline. “Based upon the results of this trial, we do not anticipate further development of serlopitant for the treatment of refractory chronic cough.
SAN DIEGO , Oct. 5, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against: PPDAI Group Inc. (NYSE: PPDF) Menlo ...
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
RADNOR, PA / ACCESSWIRE / September 25, 2018 / Kaskela Law LLC is investigating Menlo Therapeutics Inc. (NASDAQ: MNLO) ("Menloc" or the "Company") on behalf of investors. The investigation ...
NEW YORK, Sept. 24, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Menlo Therapeutics Inc.,.
In May, Menlo began enrollment in the first of the two PN Phase 3 trials which is being conducted in the U.S. The U.S. PN Phase 3 trial is more than 20% enrolled. Both PN Phase 3 trials are multi-center, randomized, double-blind, placebo‑controlled trials intended to evaluate if treatment with 5 mg serlopitant daily for ten weeks can reduce pruritus associated with PN compared with placebo.
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- American Express Company (AXP) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FBI probing pricing practices ...
LOS ANGELES, CA / ACCESSWIRE / August 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Menlo Therapeutics Inc. ("Menlo Therapeutics" or "the Company") (NASDAQ: MNLO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.